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Abstract
Background: The adipocyte-derived hormone adiponectin elicits protective functions against fatty liver diseases and
hepatic injuries at least in part by stimulating the expression of a mitochondrial inner membrane transporter, uncoupling
protein 2 (UCP2). The present study was designed to investigate the cellular and molecular mechanisms underlying
adiponectin-induced UCP2 expression.
Methodology/Principal Findnigs: Mice were treated with adiponectin and/or different drug inhibitors. Parenchymal (PCs)
and nonparenchymal (NPCs) cells were fractionated from the liver tissues for mitochondria isolation, Western blotting and
quantitative PCR analysis. Mitochondrial superoxide production was monitored by MitoSOX staining and flow cytometry
analysis. Compared to control mice, the expression of UCP2 was significantly lower in NPCs, but not PCs of adiponectin
knockout mice (AKO). Both chronic and acute treatment with adiponectin selectively increased the mRNA and protein
abundance of UCP2 in NPCs, especially in the enriched endothelial cell fractions. The transcription inhibitor actinomycin D
could not block adiponectin-induced UCP2 expression, whereas the protein synthesis inhibitor cycloheximide inhibited the
elevation of UCP2 protein but not its mRNA levels. Mitochondrial content of heterogeneous nuclear ribonucleoprotein K
(hnRNP K), a nucleic acid binding protein involved in regulating mRNA transportation and stabilization, was significantly
enhanced by adiponectin, which also evoked a transient elevation of mitochondrial superoxide. Rotenone, an inhibitor of
mitochondrial respiratory complex I, abolished adiponectin-induced superoxide production, hnRNP K recruitment and UCP2
expression.
Conclusions/Significance: Mitochondrial superoxide production stimulated by adiponectin serves as a trigger to initiate the
translocation of hnRNP K, which in turn promotes UCP2 expressions in liver.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is one of the
metabolic syndrome components closely associated with obesity,
a worldwide pandemic [1]. The presence of steatosis in liver poses
significant risks for the development of Type 2 Diabetes,
cardiovascular diseases, viral hepatitis, drug-induced hepatotoxic-
ity and alcoholic steatohepatitis [2,3,4]. In western countries,
NAFLD is the most frequent hepatic lesion with an estimated
prevalence of 10–25% [5]. About 20% to 30% of individuals with
NAFLD progress into non-alcoholic steatohepatitis (NASH),
cirrhosis and hepatocellular carcinoma [6,7].
Adiponectin is an adipocyte-derived hormone possessing a wide
range of beneficial functions against obesity-associated medical
complications [8,9,10]. The hepatoprotective activities of adipo-
nectin have been demonstrated by evidence derived from clinical,
genetic and pharmacological studies [11,12,13,14,15,16,17,18].
Epidemiological investigations suggest that low adiponectin level is
an independent risk factor for NAFLD and liver dysfunctions in
different ethnic groups [11,12,15,17,18,19,20]. In mice, adipo-
nectin deficiency leads to exacerbated liver injuries induced by
chemicals, endotoxins, alcohol consumption and obesity
[21,22,23,24], whereas administration of this protein protects
against fatty liver diseases, as well as various other forms of hepatic
injuries [17,25,26,27,28]. In adiponectin knockout (AKO) mice,
there is a pre-existing condition of hepatic steatosis and
mitochondria dysfunction, characterized by abnormal ultrastruc-
tures and defective mitochondrial respiratory chain (MRC) activity
[24]. Adiponectin treatment restores mitochondrial functions,
depletes lipid accumulation, and up-regulates the mRNA and
protein expression of uncoupling protein 2 (UCP2) in liver tissues
of AKO mice. UCP2 is a mitochondrial ion carrier encoded by
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Although the detailed physiological functions of UCP2 remain to
be elucidated, it has been suggested that increased expression of
UCP2 may help to prevent the development of hepatic steatosis
and steatohepatitis [30]. The liver protective functions of
adiponectin are significantly attenuated in UCP2 knockout mice
[24]. Administration with adiponectin or UCP2 produces similar
effects on MRC activity, fatty acyl CoA accumulation, oxidative
stress and inflammation in the liver tissues of AKO mice [31].
These information suggest that upregulation of UCP2 plays an
essential role in mediating the hepatoprotective functions of
adiponectin. On the other hand, the underlying cellular and
molecular mechanisms by which adiponectin stimulate UCP2
expression in liver are largely unknown. Results in the present
study demonstrate that adiponectin promotes UCP2 expression
selectively in nonparenchymal cells, especially in hepatic endothe-
lial cells, by provoking mitochondrial superoxide production,
which facilitates the transportation, stabilization and translation of
UCP2 mRNA.
Results
Adiponectin treatment enhanced UCP2 expressions in
nonparenchymal cells
To determine the effect of adiponectin on UCP2 expression in
parenchymal (PCs) and nonparenchymal (NPCs) cells, Western
blotting and quantitative RT-PCR (QPCR) were performed on
cells isolated from the livers of C57 and AKO mice. The protein
and mRNA abundance of UCP2 in PCs isolated from AKO mice
was not different from that in C57 mice (Figure 1A). The UCP2
protein abundance was lower in NPCs isolated from AKO mice
compared to that in C57 mice (Figure 1A, left and middle panel).
The mRNA level of UCP2 in NPCs isolated from AKO mice was
,50% of the C57 mice (Figure 1A, right panel). Administration of
adenovirus encoding adiponectin increased the protein and
mRNA abundance of UCP2 in NPCs, but not PCs, of AKO
mice (Figure 1B). Next, the effect of acute recombinant protein
treatment on UCP2 expression was evaluated. Both mitochondrial
protein abundance and the mRNA level of UCP2 was significantly
up-regulated at 30 minutes following administration of the protein
into portal vein of AKO mice liver (Figure 2, A and B). Similarly,
the elevated UCP2 expression was mainly found in NPCs
(Figure 2C).
UCP2 was induced by adiponectin treatment in hepatic
endothelial cells
Liver consists of parenchyml (PC) and nonparenchymal (NPC)
cells. Hepatocytes are the components of PCs and other cell types,
including Kupffer cells (,30%), endothelial cells (,60%), stellate
cells, and leukocytes etc, are grouped in NPCs. To further
determine the cellular target of adiponectin, enriched fractions
containing Kupffer cells and endothelial cells were used for
Western blotting to determine the mitochondrial UCP2 content.
The efficiency of cellular enrichment was validated by Western
blotting using macrophage marker F4/80 and endothelial cell
marker SE-1 (Figure 3A). Compared to that of Kupffer cells, the
protein abundance of UCP2 was much lower in endothelial cells.
While adiponectin treatment had no significant effect on UCP2
expression in Kupffer cells, it markedly increased the UCP2
content (by approximately 3-fold) in the endothelial fractions
Figure 1. UCP2 expression is decreased in NPCs of the AKO mice liver. A, PCs and NPCs were isolated from the liver tissues of C57 and AKO
mice. The protein (left and middle panel) and mRNA (right panel) expression of UCP2 was measured by Western blotting and QPCR, respectively.
SSBP-1 was used as the protein loading control and b-actin as the internal control for quantifying gene expressions. QPCR results were plotted as fold
changes against the C57 PC samples. *, P,0.05 vs C57 NPC samples, n=3. B, AKO mice were treated with adenoviruses encoding luciferase (Luci) or
adiponectin (ADN). UCP2 protein (left and middle panel) and mRNA (right panel) levels in PCs and NPCs were analyzed as above. QPCR results were
presented as fold changes against the Luci PC controls. *, P,0.05 vs corresponding controls, n=3.
doi:10.1371/journal.pone.0032349.g001
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expression in NPCs. PBS or 50 mg of murine adiponectin protein was
injected into the portal vein of AKO mice livers. Liver tissues were
collected for evaluation of UCP2 expression. The protein abundance in
mitochondria (A), mRNA expression in total tissue lysates (B), and the
protein content in PC and NPC fractions (C) were analyzed as in Figure 1.
*, P,0.05 vs vehicle treated samples, n=3.
doi:10.1371/journal.pone.0032349.g002
Figure 3. Adiponectin promotes UCP2 expression in hepatic
endothelial cells. AKO mice were treated as in Figure 1B. The NPCs
were used for further fractionation to collect those enriched with
Kupffer (K)- and sinusoidal endothelial (E) cells. The enrichment of the
two cell types were confirmed by Western blotting using macrophage
marker F4/80 and sinusoidal endothelial marker SE-1, respectively (A).
UCP2 expression was monitored as in Figure 1. After densitometry
analysis, the protein ratio of UCP2/b-actin was calculated and presented
as fold changes against Luci Kupffer samples (B). UCP2 gene expression
was also quantified in four types of cells treated with or without
adiponectin (10 mg/ml) (C). *, P,0.05 and **, P,0.01 vs corresponding
controls, n=3.
doi:10.1371/journal.pone.0032349.g003
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corroborate the cell type-specific effect of adiponectin, human
umbilical vein endothelial cells (HUVEC), hepatoma H4IIE,
macrophage RAW 264.7 and stellate LX-2 cell lines were treated
with or without adiponectin. QPCR analysis revealed that
adiponectin significantly increased UCP2 mRNA level by ,3.5-
and ,1.8-fold in HUVEC and LX-2, respectively (Figure 3C).
Consistent with the in vivo data, the UCP2 expression in hepatoma
cell H4IIE and macrophage cell RAW 264.7 was not affected by
adiponectin (Figure 3C).
Adiponectin enhanced the mRNA stability of UCP2 and
promoted hnRNP K translocation to mitochondria
To investigate the mechanism underlying adiponectin-induced
UCP2 expression, PBS or adiponectin was administered into the
portal vein of AKO mice in the presence or absence of
transcriptional inhibitor actinomycin D (ActD) or protein synthesis
inhibitor cycloheximide (CHX) (Figure 4). ActD treatment did not
block the effects of adiponectin on UCP2 expression. In the
presence of ActD, adiponectin increased the UCP2 protein and
mRNA levels by ,2.3- and ,3.2-fold, respectively (Figure 4, A
and B). The elevation of UCP2 protein expression was observed in
both PC and NPC fractions. On the other hand, CHX completely
suppressed the stimulatory effect of adiponectin on UCP2 protein
expression, which was measured in the lysates derived from both
the AKO liver tissues and the NPC fractions (Figure 4, A and D).
However, CHX did not prevent adiponectin-induced elevation of
UCP2 mRNA expression (Figure 4B).
Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is
involved in regulating UCP2 mRNA stability and protein synthesis
[32]. While the total hnRNP K protein expression was not
Figure 4. Adiponectin enhances the mRNA stability of UCP2 and promotes its protein synthesis. Two inhibitors, actinomycin D (ActD, A,
B and C) or cycloheximide (CHX, A, B and D), were administered together with or without adiponectin protein into liver tissues of AKO mice livers. The
protein (A) and mRNA (B) abundance of UCP2 was monitored by Western blotting and QPCR, respectively. The relative protein expression was also
monitored in PCs/NPCs lysates (C and D). *, P,0.05 vs corresponding controls, n=3.
doi:10.1371/journal.pone.0032349.g004
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shown), the abundance of this protein was much lower in the
mitochondria fractions of AKO mice liver compared to those of
C57 mice (Figure 5A). Adenovirus-mediated chronic over-
expression of adiponectin significantly elevated hnRNP K levels
in mitochondria isolated from AKO mice (Figure 5B, top panel).
Similarly, injection of recombinant adiponectin, via portal vein,
also increased the mitochondrial hnRNP K protein content
(Figure 5B, bottom panel). UCP2 mRNA is transported to
mitochondria-associated polysomes for protein synthesis. A
123 bp specific fragment of UCP2 mRNA was amplified from
mitochondrial RNA samples (Figure 5C). The mitochondrial
contents of UCP2 mRNA were quantified by QPCR using the
mitochondrial gene cytochrome C oxidase subunit II (COX II) as
the internal control (Figure 5D). It was found that UCP2 mRNA
content in the mitochondria-associated polysome fraction of AKO
mice was only ,29.1% of that in the C57 group. Adiponectin
replacement by either adenovirus administration or portal vein
injection restored the UCP2 mRNA contents (Figure 5D).
Treatment with rotenone, a MRC complex I inhibitor,
abolished adiponectin-mediated induction of UCP2 and
hnRNP K translocation
Western blotting was performed on mitochondria protein
lysates of AKO mice treated with recombinant adiponectin in
the presence or absence of of MRC complexes inhibitors,
including rotenone (Rot, complex I inhibitor), antimycin A (AntA,
complex III inhibitor) and sodium azide (NaN3, complex IV
inhibitor). The stimulatory effect of adiponectin on mitochondrial
UCP2 protein expression was significantly attenuated by rotenone,
but not by antimycin A or NaN3 (Figure 6A). Adiponectin-induced
elevation of UCP2 mRNA level was also attenuated by rotenone
treatment (Figure 6B). This inhibitor mainly blocked the
expression of UCP2 in NPCs (Figure 6C). Rotenone treatment
also prevented adiponectin-induced mitochondria translocation of
hnRNP K in NPCs (Figure 6D).
MRC is a major source of reactive oxygen species (ROS), which
stimulate UCP2 expression [33,34,35]. By applying a fluorescent
probe for mitochondrial superoxide, MitoSOX, it was found that
Figure 5. Mitochondrial content of hnRNP K protein is decreased in AKO mice. Mitochondria were isolated from C57 mice and AKO mice
(A), or AKO mice subjected to chronic or acute treatment with adiponectin (B). hnRNP K protein content in mitochondrial fractions was measured by
Western blotting (A and B). RNA was extracted from the mitochondrial fractions and used for QPCR analysis. The PCR products were visualized in
agarose gel for confirming the specific products (C). The QPCR results were compared and presented as fold changes against C57 samples (D). The
gene encoding COXII was used as the internal control. *, P,0.05 vs corresponding controls, n=3.
doi:10.1371/journal.pone.0032349.g005
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burst (Figure 7A). This was concomitantly associated with the
elevation of UCP2 expression and the recruitment of hnRNP K
into mitochondrial fractions as shown in Figure 2 and 5,
respectively. Note that the positive MitoSOX staining signal was
found to be either co-localized with or close to that of von
Willebrand factor (VWF), a marker for endothelial cells
(Figure 7B). Flow cytometric analysis further confirmed that
adiponectin could induce a short burst of mitochondrial
superoxide production in HUVEC, which was detected at
30 minutes of treatment. The elevation of ROS was no longer
detectable after 1.5 hours (Figure 7C). Adiponectin could not
promote the transient induction of mitochondrial superoxide in
H4IIE hepatoma cells (data not shown). Treatment with rotenone,
but not antimycin A and NaN3, blocked adiponectin-induced
mitochondrial superoxide production in HUVEC (Figure 7D).
Inhibition of the NADPH oxidase by diphenylene iodonium
(0.5 mM) or apocynin (1 mM) had no significant effect on
adiponectin-evoked ROS generation and UCP2 expression (data
not shown).
Discussion
Uncoupling protein 2 (UCP2) is a mitochondrial inner
membrane carrier protein encoded by nuclear genome [30].
The first member of uncoupling protein family, UCP1, was
discovered as a physiologic mediator of proton leak and cold-
adapted thermogenesis in brown adipose tissue [36]. UCP2
protein shares 59% amino acid identity to that of UCP1 [37].
However, the biological functions of UCP2 remain poorly defined.
Nevertheless, a growing body of evidence suggests that UCP2
plays a beneficial role in various stages of fatty liver diseases and
could exert anti-steatotic and anti-inflammatory activities through
promoting mitochondrial respiration, attenuating non-esterified
mitochondrial fatty acid accumulation and ROS production,
inhibiting inflammatory cytokine expression and activating AMP-
activated protein kinase [30,31,33,35]. In mice, absence of UCP2
is associated with elevated production of ROS, increased oxidative
stress, and delayed liver regeneration [33,34,35,38,39]. On the
contrary, there lacks sufficient information on whether replace-
ment with UCP2 could alleviate NAFLD [30]. In fatty liver tissues,
the lipid-laden hepatocytes express high levels of UCP2, whereas
the expression of UCP2 in Kupffer cells decreases [40]. The
present study demonstrates that UCP2 expression is significantly
reduced in NPCs, but not PCs fractions of AKO livers. Moreover,
administration with adiponectin selectively promotes UCP2
expression in hepatic endothelial cells. These evidence suggest
that a cell-specific regulation of UCP2 may be crucial for
adiponectin to elicit its hepatoprotective functions.
The mitochondrial superoxide anion radicals (O2N
2) are
generated as the by-products of oxidative phosphorylation, from
electrons leakage at complex I and III of the electron transport
Figure 6. Rotenone inhibits adiponectin-stimulated UCP2 expression and hnRNP K translocation to mitochondria. Mitochondrial
respiration chain inhibitors, including rotenone (Rot), sodium azide (NaN3) and antimycin A (AntA) were administered into liver tissues of AKO mice as
described in Methods. The effects of each inhibitor on adiponectin-induced UCP2 protein expression in mitochondria of liver tissues (A), UCP2 mRNA
expression in total tissue lysates (B) were evaluated. The mitochondria protein content of UCP2 (C) and hnRNPK (D) in PCs and NPCs were compared
by Western blotting. *, P,0.05 vs corresponding controls, n=3.
doi:10.1371/journal.pone.0032349.g006
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signalling messengers for many biological responses, including the
antioxidant mechanisms for restoring cellular redox homeostasis
[42,43,44]. Here, the results demonstrate that adiponectin
treatment induces the generation of mitochondrial superoxide,
which can be inhibited by rotenone, the complex I inhibitor but
not by antimycin A, the complex III inhibitor. Complex I (H
+-
pumping NADH:quinone oxidoreductase) plays an important role
not only in cell respiration, but also in cellular/organismal ROS
homeostasis [45]. Complex I-derived O2N
2 production due to
reverse electron transport can be inhibited by rotenone and is
sensitive to the pH gradient across the mitochondrial inner
membrane [46,47]. The high rate of superoxide production by
complex I could be abolished by uncoupler [48,49]. However, the
mechanisms of superoxide production by complex I are less clear
than that of complex III. Nevertheless, the results of the present
study suggest that adiponectin preferentially acts through a
rotenone-sensitive and complex I-related pathway to induce the
superoxide burst and the expressions of UCP2 (Figure 8). Elevated
UCP2 subsequently maintains low ROS production in the
mitochondrial matrix [38].
Both adenovirus-mediated chronic overexpression of adiponec-
tin and acute injection of the recombinant protein elevate mRNA
and protein levels of UCP2 in mitochondria. Transcription
inhibitor actinomycin D does not affect the ability of adiponectin
to stimulate UCP2 expression. Adiponectin stabilizes and facilitate
the transportation of UCP2 transcripts to mitochondria-associated
polysomes for protein synthesis, which involves hnRNP K, a
nucleic acid binding protein. Different hnRNP proteins affect
distinct sets of targets. hnRNP K is one of those showing the
broadest effects on regulating mRNA transcription, stability and
translation of genes involved in the control of apoptosis, oxidative
stress, oncogenesis and metabolism [50]. A large number of RNAs
associated with hnRNP K are nuclear-encoded but expressed in
mitochondria, including UCP2 [51]. Translocation of hnRNP K
from nuclear to cytoplasm and the importation of this protein into
mitochondria have also been implicated in regulating mitochon-
drial genome transcription [52]. hnRNP K binds with the 39-
untranslated region and increases the abundance of UCP2 mRNA
in mitochondria [32]. Mitochondria content of hnRNP K in AKO
livers is much lower than that of C57 mice. Similar to UCP2
elevation, adiponectin-induced mitochondrial translocation of
hnRNP K can also be inhibited by rotenone treatment. These
evidence indicate that adiponectin-induced hnRNP K transloca-
tion to mitochondria could be a downstream response to the
transient mitochondria superoxide production (Figure 8). Indeed,
previous studies have suggested that a number of redox-linked
signal transduction pathways, such as protein kinase C [53], c-Jun
N-terminal kinases [54], c-Src [55], and extracellular signal
regulated kinases [56], are involved in the activation of hnRNP K.
In summary, the present study demonstrates that adiponectin
treatment in liver induces a transient superoxide production from
mitochondria, which initiates a signalling event for UCP2 up-
regulation through hnRNP K (Figure 8). Based on experiments
with pharmacologic inhibitors, complex I inhibition (with
rotenone) but not complex IIII inhibition (with antimycin A)
decreases the superoxide generation induced by adiponectin. To
characterize the specific sites of superoxide generation and the
downstream ROS signals may be attractive targets for the
development of adiponectin-based hepatoprotective therapies.
Materials and Methods
Materials
Sodium azide (NaN3), rotenone (Rot), antimycin A (AntA),
cycloheximide (CHX) and antinomycin D (ActD) were purchased
from Sigma Aldrich (St. Louis, MO, USA). Dulbecco’s modified
Eagle’s medium (DMEM) and mito-hydroethidine [MitoSox, 3,8-
phenanthridine diamine, 5-(69-triphenyl phosphonium hexyl)-5,6
dihydro-6-phenyl] were purchased from Molecular Probes (In-
vitrogen, Carlsbad, CA). Bicinchoninic acid (BCA) protein
quantitation kit was purchased from Pierce Biotechnology Inc.
(Rockford, IL, USA). Polyvinylidene fluoride (PVDF) membrane
and chemiluminescence solution were obtained from GE Health-
care (Piscataway, NJ, USA). Unless otherwise stated, all chemicals
were purchased from USB Corporation (Cleveland, Ohio, USA).
Rat hepatoma cell H4IIE, human umbilical vein endothelial cell
Figure 7. Adiponectin treatment induces transiently elevates
mitochondrial superoxide. Liver sections (A and B) and HUVEC
samples (C) were prepared before and at different time points after
vehicle (PBS) or adiponectin treatment. MitoSOX and VWF staining was
performed as described in Methods. Note that rotenone (Rot) but not
NaN3 or antimycin A (AntA) blocked the induction of mitochondria
superoxide by adiponectin (C). Magnification, 4006.
doi:10.1371/journal.pone.0032349.g007
Adiponectin and Liver
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from ATCC (Manassas, VA, USA). Human stellate cell LX2 was a
kind gift from Dr George K. K. Lau (Clinical Trial Center, the
University of Hong Kong). Cells were cultured with DMEM
containing 10% FBS, 100 U/ml penicillin and 100 mg/ml
streptomycin at 37uC in a humidified atmosphere of 5% CO2.
Murine adiponectin recombinant protein was purified as described
[57].
Animal studies
C57BL/6J mice were purchased from the Jackson Laboratory
(Bar Harbor, ME, USA). AKO mice in C57BL/6 background was
a kind gift from Prof. Lawrence Chan (Baylor College of Medicine,
Houston,TX, USA) [24]. All animals were kept under 12-hour
light-dark cycles at 22–24uC. The mice were fed with standard
chow containing 20% protein, 10% fat and 70% carbohydrates
(LabDiet 5053, Purina mills. Richmond, IN). Male mice at the age
of 6–8 weeks were used for this study. Adenovirus expressing
luciferase or adiponectin was administered into mice by tail vein
injection at the optimal dosage of 1610
8 pfu per mouse [24,31].
For drug treatment, actinomycin D (5 mg/ml), cycloheximide
(40 mg/ml), rotenone (20 mM), NaN3 (2% w/v) or antimycin A
(20 mM) in 100 ml PBS were injected into portal vein with or
without adiponectin. All animal experimental procedures were
approved by the Committee on the Use of Live Animals for
Teaching and Research, the University of Hong Kong (No 1655-
08), and carried out in accordance with the Guide for the Care
and Use of Laboratory Animals published by the US National
Institutes of Health (NIH publication 86-23 revised 1985).
Isolation of PCs and NPCs from liver tissues
Mice were sacrificed under deep anaesthesia. Liver perfusion
was performed as described [58]. After removing cellular
aggregates and tissue debris, cell suspensions were filtered through
a cell strainer (mesh width 100 mm). PCs were enriched by low
speed centrifugation (500 g) for three minutes at 4uC. The NPCs
supernatant was saved for further fractionation using a two-step
Percoll gradient (50% at the bottom and 25% in the upper layer).
After centrifuging at 800g for 15 minutes at 4uC, endothelial cells-
enriched fractions were collected from the intermediate zone
between the two Percoll layers. Fractions containing Kupffer cells
were obtained from the 50% Percoll layer. Mitochondria were
isolated from total liver lysates, PCs and NPCs by following the
protocol described previously [24].
In vivo and in vitro detection of mitochondrial reactive
oxygen species (ROS)
Mitochondrial superoxide was detected by MitoSOX RED
TM,
a fluorescent probe targeted to mitochondria. MitoSOX exhibits
fluorescence after oxidation by superoxide (excitation 510 nm,
emission 580 nm). For in vivo evaluation, MitoSOX with or
without adiponectin (50 mg per mouse) in a total volume of 100 ml
was administered into portal vein. The liver tissues were collected
at different time points for preparing the 5 mm cryo-sections. After
fixation in ice-cold acetone and counter-stained with DAPI,
images were captured with Olympus BX41 microscope (Olympus,
Tokyo, Japan). von Willebrand factor (VWF) was used as an
endothelial cell marker for immuno-staining in the liver tissue
sections. For determination of mitochondrial superoxide by flow
cytometry, HUVEC were preloaded with 5 mM MitoSOX for
30 min in medium without phenol red. After washing, adiponectin
with or without various inhibitors were added into the cells for
different periods prior to flow cytometric measurement [59].
Triplicate experiments were carried out for each set. The data
were presented by histogram of mean intensity of MitoSOX
fluorescence. The analysis was performed on the Cytomics FC 500
(Becman-Coulter, CA, USA).
Real time quantitative polymerase chain reaction (QPCR)
The cDNA reversely transcripted from total RNA was used to
analyze gene expression levels. Fluorescent SYBR Green (Qiagen,
Hilden,Germany) was used to quantify the PCR product on an
Applied Biosystems Prism 7000 sequence detection system. The
primer sequences were: Forward 59-GGATACTGCTAAAG-
TCCGGT-39 and Reverse 59-CCATTGTAGAGGCTTCGGG-
39 for UCP2 (NM_003355.2); Forward 59-TAGTGCGCACCG-
CAGCC-39 and Reverse 59-AGCTCATCTGGCGCTGCAG-39
for mouse Ucp2 (NM_011671.4); Forward 59-GAGAGT-
CAAGGGCTAGCGC-39 and Reverse 59-GCTTCGACAGTG-
CTCTGGTA-39 for rat Ucp2 (NM_001130033.1); Forward 59-
Figure 8. A schematic summary: Adiponectin-evoked transient elevation of mitochondrial O2N
2 serves as a trigger for the
translocation hnRNP K, which subsequently promotes the stabilization of UCP2 mRNA and its protein synthesis in mitochondria of
hepatic endothelial cells.
doi:10.1371/journal.pone.0032349.g008
Adiponectin and Liver
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CATCACGATGCCAGT-39 for human ACTB (NM_001101.3);
Forward 59-AGTGTGACGTTGACATCCGT-39 and Reverse
59- CCACCGATCCACACAGAGTA-39 for mouse Actb
(NM_007393.3); Forward 59-CACCCGCGAGTACAACCTTC-
39 and Reverse 59-CCCATACCCACCATCACACC-39 for rat
Actb (NM_031144.2); Forward 59-ACGAAATCAACAACC-
CCGTA-39 and Reverse 59-GGCAGAACGACTCGGTTATC-
39 for mouse MT-Co2 (NC_005089.1). b-actin gene (ACTB or Actb)
was used as the QPCR internal control for cell and tissue RNA
samples. Cytochrome C oxidase II (COXII) gene (MT-Co2) was
used as the internal control for mitochondrial polysome-associated
RNA samples. The amplified products were checked by separation
on a 2% agarose gel.
Western blotting
Tissues were homogenised in lysis buffer [20 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1%
Nonidet P 40, 0.1% (w/v) SDS, 1% (w/v) sodium deoxycholate,
1 mM NaF, 1 mM Na3VO4, 1% (v/v) protease inhibitor cocktails
(Roche, Mannheim, Germany)]. Protein lysates were heated at
95uC for 5 min, separated by SDS-PAGE, and transferred to
PVDF membrane for immunoblotting with the specific antibodies
against UCP2 (R&D Systems, #AF4739), single-strand binding
protein-1 (SSBP-1, Santa Cruz, #sc-34727), liver sinusoidal
endothelial cell marker SE-1 (Novus Biologicals, NB110-68095),
F4/80 (Abcam, #ab6640), hnRNP K (Santa Cruz, #sc-25373) or
b-actin (Sigma, #A5316). Immune-complexes were visualized
using enhanced chemilumincesence. SSBP-1 and b-actin were
used as loading controls for mitochondrial and total cell lysates,
respectively.
Statistical analysis
All results were derived from at least three sets of experiments.
The density of protein bands in Western blotting results were
quantitatively analyzed by ImageJ software for calculating the
expression ratios against loading control. Representative Western
blotting images were shown. Values are expressed as mean 6
SEM. The statistical calculations were performed with the
Statistical Package for the Social Sciences version 11.5 software
package (SPSS, Inc., Chicago, IL). Differences between groups
were determined by Student’s t-test. Comparisons with P,0.05
were considered as statistically significant.
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